
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
New infections are decreasing, but U.S. statistics reveal some significant disparities.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) published a

